CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage

Pipeline progress continues with first patient dosed and ongoing enrollment in multiple clinical trials across the depression and neurology franchises Durability of response was observed in patients with MDD who responded to a 2-week treatment with zuranolone in MOUNTAIN Study six-month follow-up

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at

Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M , with significant portion related to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

Changes are expected to result in annualized cost savings of approximately $170 million , including SG&A savings of $150 million Headcount reduction of 340 – approximately 53 percent of workforce Current balance of cash, cash equivalents, restricted cash, and marketable securities expected to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on April 1, 2020 , the